Changes in the Fibrinolytic System During Pregnancy

Bonnar, J.; Daly, L.; Sheppard, B. L.

doi:10.1055/s-2007-1002673

Cited by 33 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the numbers of subjects examined in this study is not large, it shows clearly that levels of the two inhibitors vary independently in pre‐eclampsia, levels of PAI‐1 being significantly increased as compared to those in normal pregnant individuals, while levels of PAI‐2 are reduced compared with those seen in normal pregnancy. As in other studies (Bonnar et al 1990) overlap in the values between pre‐eclamptic and nonpre‐eclamptic individuals was observed. When the ratio of PAI‐1 to PAI‐2 was calculated, clearer discrimination between pre‐eclampsia and normal pregnancy patients was established, the ratio in normal pregnancy being approximately 0.6 while that in pre‐eclampsia was 2.5; total discrimination between the normal and the abnormal state was not, however, achieved by this treatment of the data.…”

Section: Discussionsupporting

confidence: 85%

“…In normal pregnancy, levels of both inhibitors in plasma rise, PAI‐1 to maximum levels of over 100 ng/ml and PAI‐2 to 200 ng/ml at 30–35 weeks gestation. It seemed likely that altered levels of one or both of these inhibitors might account for the increase in t‐PA inhibitor activity in the systemic and uterine vessels in subjects with severe pre‐eclampsia (Estelles et al 1987, Bonnar et al 1990).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasminogen activator inhibitors (PAI‐1 and PAI‐2) in normal pregnancies, pre‐eclampsia and hydatidiform mole

Reith¹,

Booth²,

Moore³

et al. 1993

BJOG

View full text Add to dashboard Cite

Objective To examine the behaviour of the major inhibitors of fibrinolysis (PAI‐1 and PAI‐2) in normal pregnancy and pregnancy complicated by either pre‐eclampsia or hydatidiform mole. Design Prospective study. Setting Antenatal Clinic and Maternity Hospital. Subjects Eleven women with established pre‐eclampsia and eleven women, matched by age, parity, and duration of pregnancy who were undergoing uncomplicated pregnancy. Two women having surgery for hydatidiform mole. Main outcome measure Plasma levels of PAI‐1 and PAI‐2 antigens determined by sensitive specific ELISA. Functional identification of PAI‐2 by nondenaturing gel electrophoresis with overlay zymography. Results In pre‐eclampsia PAI‐2 antigen was significantly lower than in normal pregnancy (105.3 ± 34.9 versues 187.1 ± 67.9 ng/ml; P<0.001). In contrast PAI‐1 antigen was significantly higher in pre‐eclampsia than in normal pregnancy (170.7 ± 71.2 versus 113.8 ± 35.6 ng/ml; P<0.05). In consequence the ratio of PAI‐1/PAI‐2 increased markedly in pre‐eclampsia (2.5 versus 0.6). No PAI‐2 was detected in plasma of women with hydatidiform moles. Conclusions PAI‐2 levels fell significantly in pre‐eclampsia probably as a result of decreased placental mass or function. The raised PAI‐1 level in pre‐eclampsia may reflect a response to hypertension or renal damage that is not specific to pregnancy or may reflect altered placental function. The use of the ratio of PAI‐1/PAI‐2 assists in separating normal from abnormal pregnancies.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Plasminogen activator inhibitors (PAI‐1 and PAI‐2) in normal pregnancies, pre‐eclampsia and hydatidiform mole

Reith¹,

Booth²,

Moore³

et al. 1993

BJOG

View full text Add to dashboard Cite

show abstract

“…Most investigators have found plasminogen levels to increase during pregnancy 32,33 . Bonnar et al 23 found that the increase in plasminogen levels occurred at the same time as the increase in fibrinogen, the proportional rate of increase in the third trimester being of the order of 50 to 60 % with both fibrinogen and plasminogen. High plasminogen levels might be a protective measure against over‐activation of clotting.…”

Section: Discussionmentioning

confidence: 99%

Coagulation and fibrinolysis in smoking and nonsmoking pregnant women

Mercelina-Rournans

Ubachs

Wersch

1996

BJOG

View full text Add to dashboard Cite

Objective To assess the effects of smoking during pregnancy on coagulation and fibrinolysis. Design A cross‐sectional study. Setting A teaching hospital in Heerlen, The Netherlands. Results Parameters of coagulation activation increased significantly with gestational age. The values presented are median values. Prothrombin fragment 1+2 increased from 0.8 to 25 nmol/l in the nonsmoking group of pregnant women and from 1.0 to 1.8 nmol/l in the smoking group. Thrombin‐antithrombin III (TAT) levels increased from 2.2 to 9.9 μg/l in the nonsmoking group and from 3.1 to 8.5 μg/1 in the smoking group. Parameters of fibrinolysis showed a different picture. Plasminogen levels in both groups rose significantly in the first half of gestation reaching a plateau in the second half. The α2‐antiplasmin levels remained constant in both groups, although the smokers started with significantly higher levels: 119 versus 105 % in the nonsmokers. The D‐dimer levels rose significantly in both groups: from 278 to 847 μg/ml in the nonsmokers and from 215 to 520 μg/ml in the smokers. They were significantly lower in the smoking group from the 11th up to the 40th weeks. The D‐dimer/TAT ratio was significantly higher in the nonsmokers. Conclusions In smoking pregnant women the activated coagulation process was not counterbalanced by an adequate increase of fibrinolysis which was the case in the nonsmokers.

show abstract

“…Extensive placental infarction in patients with preeclampsia is associated with marked immunoreactivity for components of the PA system (23)(24)(25). A markedly increased PAI-1 concentration in umbilical cord plasma has also been shown in pregnancies complicated by preeclampsia (19,26 ). This might also lead to enhanced release of PAI-1 and tPA mRNA into maternal plasma.…”

Section: Discussionmentioning

confidence: 99%

Cell-Free mRNA Concentrations of Plasminogen Activator Inhibitor-1 and Tissue-Type Plasminogen Activator Are Increased in the Plasma of Pregnant Women with Preeclampsia

et al. 2007

View full text Add to dashboard Cite

Background: Detection of placental mRNA in maternal plasma has been reported in high-risk pregnancies. We attempted to investigate the concentrations of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (tPA) mRNA in maternal plasma in preeclampsia. Methods: Peripheral blood samples were obtained from healthy pregnant women before and after delivery and also from women with or without preeclampsia. Plasma was isolated from these samples, and RNA was extracted. Plasma PAI-1 and tPA mRNA concentrations were then measured by use of reverse transcription PCR assays. The concentrations were converted into multiples of the median (MoM) of the controls adjusted for gestational age. Data were stratified and analyzed according to the clinical severity of preeclampsia and quantitative distribution of blood pressure and proteinuria. Results: The median (minimum-maximum) PAI-1 mRNA MoM values for women with preeclampsia and controls were 2.48 (0.82-8.53) and 1.00 (0.41-2.33), respectively, whereas the median (minimum-maximum) tPA mRNA MoM values were 3.33 (1.01-10.58) and 1.00

show abstract

Changes in the Fibrinolytic System During Pregnancy

Cited by 33 publications

References 30 publications

Plasminogen activator inhibitors (PAI‐1 and PAI‐2) in normal pregnancies, pre‐eclampsia and hydatidiform mole

Plasminogen activator inhibitors (PAI‐1 and PAI‐2) in normal pregnancies, pre‐eclampsia and hydatidiform mole

Coagulation and fibrinolysis in smoking and nonsmoking pregnant women

Cell-Free mRNA Concentrations of Plasminogen Activator Inhibitor-1 and Tissue-Type Plasminogen Activator Are Increased in the Plasma of Pregnant Women with Preeclampsia

Contact Info

Product

Resources

About